Date: 2015-08-27
Type of information: Company acquisition
Acquired company: Calibrium (USA - IL)
Acquiring company: Novo Nordisk (Denmark)
Amount: undisclosed
Terms: * On August 27, 2015, Novo Nordisk announced that it has entered into a definitive agreement under which Novo Nordisk will acquire Calibrium LLC and MB2 LLC, two privately held biopharmaceutical research companies based in Indiana, US. The parties have agreed not to disclose the financial details of the transactions. The acquisition will expand Novo Nordisk\'s portfolio of projects and intellectual property rights within diabetes and obesity and provide a basis for expanding Novo Nordisk\'s research presence in the US.
Details: Formed in 2013, Calibrium is an emerging biopharmaceutical company focused on the discovery and early development of novel peptides for the treatment of diabetes and related metabolic diseases. Calibrium was co-founded by Fritz French, chief executive officer, and Richard DiMarchi, PhD, chief scientific officer.
Related: Diabetes Metabolic diseases
